| Date | Title | Description | |
|---|---|---|---|
| 08 May 2025 | On business and financial situation | The Company releases the first three months 2025 financial results presentation | Download |
| 08 May 2025 | Announcement of General Shareholders’ Meeting | The Company announces the call of its 2025 Ordinary General Shareholders' Meeting | Download |
| 08 May 2025 | On business and financial situation | ROVI informs on the award of a grant in its favor to develop the R&D Project IPCEI - ROVI (LAISOLID) | Download |
| 08 May 2025 | On business and financial situation | The Company releases the press release related to the first three months of 2025 financial results | Download |
| 04 Apr 2025 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the first quarter of 2025 | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 06 Apr 2017 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted in the first quarter of 2017 | Download |
| 13 Mar 2017 | Otros sobre negocio y situación financiera | The Company releases the presentation related to its biosimilar of Enoxaparin | Download |
| 07 Mar 2017 | Otros sobre negocio y situación financiera | ROVI informs that the Decentralised procedure used for the registration of its biosimilar of enoxaparin has been completed with positive outcome | Download |
| 16 Feb 2017 | Otros sobre Gobierno Corporativo | The Company informs about the agreements adopted by the Board of Directors | Download |
| 16 Feb 2017 | Informe anual de remuneraciones de los consejeros | ROVI releases the 2016 annual report regarding remuneration of the members of the Board of Directors | Download |